LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. It operates through three segments: Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products. The Neuromodulation segment designs, develops, and markets VNS Therapy System, an implantable device that delivers vagus nerve stimulation (VNS) therapy for the treatment of drug-resistant epilepsy, difficult-to-treat depression, and obstructive sleep apnea. It is also involved in the development and clinical testing of the VITARIA System for treating heart failure through VNS.[ Read More ]
The intrinsic value of one LIVN stock under the base case scenario is HIDDEN Compared to the current market price of 52.1 USD, LivaNova PLC is HIDDEN
Current Assets | 988 M |
Cash & Short-Term Investments | 267 M |
Receivables | 215 M |
Other Current Assets | 507 M |
Non-Current Assets | 1.44 B |
Long-Term Investments | 22.8 M |
PP&E | 205 M |
Other Non-Current Assets | 1.21 B |
Current Liabilities | 335 M |
Accounts Payable | 80.8 M |
Short-Term Debt | 26.5 M |
Other Current Liabilities | 228 M |
Non-Current Liabilities | 817 M |
Long-Term Debt | 614 M |
Other Non-Current Liabilities | 203 M |
Revenue | 1.15 B |
Cost Of Revenue | 382 M |
Gross Profit | 771 M |
Operating Expenses | 844 M |
Operating Income | -68.5 M |
Other Expenses | -86 M |
Net Income | 17.5 M |
Net Income | 17.5 M |
Depreciation & Amortization | 60.9 M |
Capital Expenditures | -35 M |
Stock-Based Compensation | 36.4 M |
Change in Working Capital | -34.6 M |
Others | 113 M |
Free Cash Flow | 39.9 M |
Date | Value | Insider | Amount | Avg Price |
---|---|---|---|---|
2 months ago
Sep 11, 2024
|
Sell 69.9 K USD
|
Bianchi Francesco
Director |
- 1500
|
46.58 USD |
5 months ago
Jun 03, 2024
|
Sell 3.28 M USD
|
Moore Daniel Jeffrey
Director |
- 54578
|
60.075 USD |
5 months ago
Jun 03, 2024
|
Sell 125 K USD
|
Moore Daniel Jeffrey
Director |
- 2045
|
61.086 USD |
1 year ago
Mar 30, 2023
|
Sell 94.5 K USD
|
McDonald Damien
CEO |
- 2220
|
42.55 USD |
1 year ago
Dec 15, 2022
|
Sell 121 K USD
|
McDonald Damien
CEO |
- 2220
|
54.56 USD |
2 years ago
Apr 01, 2022
|
Sell 83.4 K USD
|
Moore Daniel Jeffrey
director: |
- 1000
|
83.416 USD |
2 years ago
Mar 29, 2022
|
Sell 227 K USD
|
McDonald Damien
CEO |
- 2784
|
81.5 USD |
2 years ago
Mar 02, 2022
|
Sell 80 K USD
|
Moore Daniel Jeffrey
director: |
- 1000
|
80 USD |
2 years ago
Feb 25, 2022
|
Sell 80 K USD
|
Moore Daniel Jeffrey
Director |
- 1000
|
80 USD |
2 years ago
Jan 03, 2022
|
Sell 85.9 K USD
|
Moore Daniel Jeffrey
Director |
- 1000
|
85.9341 USD |
2 years ago
Dec 13, 2021
|
Sell 227 K USD
|
McDonald Damien
CEO |
- 2784
|
81.5 USD |
2 years ago
Dec 01, 2021
|
Sell 81.7 K USD
|
Moore Daniel Jeffrey
Director |
- 1000
|
81.734 USD |
3 years ago
Nov 10, 2021
|
Sell 58.5 K USD
|
Novak Alfred J
Director |
- 644
|
90.7659 USD |
3 years ago
Nov 11, 2021
|
Sell 208 K USD
|
Novak Alfred J
Director |
- 2337
|
89.1729 USD |
3 years ago
Nov 10, 2021
|
Bought 90.4 K USD
|
KOZY WILLIAM A
Director |
+ 1000
|
90.4282 USD |
3 years ago
Nov 03, 2021
|
Sell 85.2 K USD
|
Moore Daniel Jeffrey
Director |
- 1000
|
85.25 USD |
3 years ago
Oct 01, 2021
|
Sell 80 K USD
|
Moore Daniel Jeffrey
Director |
- 1000
|
80 USD |
3 years ago
Sep 01, 2021
|
Sell 82.4 K USD
|
Moore Daniel Jeffrey
Director |
- 1000
|
82.4015 USD |
3 years ago
Aug 02, 2021
|
Sell 86.4 K USD
|
Moore Daniel Jeffrey
Director |
- 1000
|
86.3886 USD |
3 years ago
Jun 29, 2021
|
Sell 84.2 K USD
|
Moore Daniel Jeffrey
Director |
- 1000
|
84.2 USD |
3 years ago
May 18, 2021
|
Sell 84.8 K USD
|
Dolci Marco
SVP Global Operations, R&D |
- 1019
|
83.2259 USD |
3 years ago
May 18, 2021
|
Sell 602 K USD
|
Dolci Marco
SVP Global Operations, R&D |
- 7259
|
82.8654 USD |